Tango Therapeutics Hits New 52-Week High of $13.60, Up 77.79%

Tango Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.60 on February 23, 2026. This achievement underscores the company's remarkable performance, with a one-year growth rate of 77.79%, significantly outpacing the S&P 500's 12.95% return during the same period. The company's market capitalization stands at USD 1,643 million, reflecting its position within the small-cap segment. Despite being loss-making, Tango Therapeutics has demonstrated impressive growth in net sales, soaring by 1591.64%. This growth trajectory is complemented by a notable recovery, as the company reported positive results after three consecutive quarters of losses. Tango Therapeutics also boasts a high institutional ownership rate of 100%, indicating strong confidence from institutional investors who typically possess greater analytical resources. The stock's performance has consistently outperformed the broader market, generating substantial returns over the past year and beyond. As it continues to navigate the competitive landscape of the biotechnology industry, this new high marks a pivotal moment for Tango Therapeutics.